Examining gender differences in opioid, benzodiazepine, and antibiotic prescribing

Tymor Hamamsy^{1¶*}, Suzanne Tamang^{2¶}, Anna Lembke^{3¶}

1 Center for Data Science, New York University, New York, New York, United States of America

2 Biomedical Data Science, Stanford University School of Medicine, Stanford, California, United States of America

3 Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, United States of America

* Corresponding author

E-mail: tch362@nyu.edu

¶ These authors contributed equally to this work.

Abstract

While gender differences have been explored across several areas of medicine, our study is the first to present a systematic comparison of drug prescribing behavior of male and female providers, including opioid, benzodiazepine, and antibiotic prescribing. Our work is of particular relevance to the current opioid crisis and other iatrogenic harms related to injudicious prescribing. Our objective is to explore prescribing differences between male and female providers across medical specialties and for different prescription drug categories in Medicare Part D. To this end, we performed a descriptive, retrospective study of 1.13 million medical providers who made drug claims to Medicare Part D in 2016, analyzing by gender, specialty, and drug category. We found that male providers across diverse specialties prescribe significantly more medications, including opioids, benzodiazepines, and antibiotics than female providers by volume, cost, and per patient. These observed gender differences in prescribing, while agnostic to the quality of care provided, nonetheless inform the design of prevention strategies that seek to reduce iatrogenic harms related to prescribing.

Introduction

Opioid, benzodiazepine, and antibiotic prescribing has been linked to increased morbidity and mortality in the United States. Among the more than 11 million people who misuse prescription opioids, the majority gets them directly or indirectly from a prescription.¹ Among heroin users, 75% were first exposed to opioids through a prescription.² Benzodiazepine prescriptions have increased over 67% since 1999, and have

contributed to an almost eight fold increase in mortality rates due to benzodiazepine overdoses, especially when combined with opioids.³

Antibiotic resistance, a result of antibiotic overprescribing, has the potential to affect people at any stage of life, and poses substantial risks to the viability of the healthcare, veterinary, and agriculture industries, making it one of the world's most urgent population health problems.⁴

We examined differences in opioid, benzodiazepine, antibiotic, and overall prescribing among male and female Medicare Part D prescribers (2016). As we consider tailored interventions to educate prescribers about the problems of overprescribing, physician factors that drive prescribing take on heightened urgency.

Methods

We analyzed data from Medicare Part D prescribers from 2016 drug claims submitted to the Centers for Medicare and Medicaid Services (CMS). Collectively, there were 40.4 million Medicare Part D patients, and over 1.4 billion Medicare Part D claims, costing over \$146 billion. This is a nationally representative sample of Medicare beneficiaries, in which 85% are over 65.

For each of the 1.13 million unique Medicare Part D prescribers, we mapped the 223 clinical specialties to broader, more common names, based on the CMS provider taxonomy code set. We focused on the potential influence of gender on the number of provider's patients a provider sees, by exploring the total drug, opioid, and antibiotic beneficiaries of doctors, controlling for the provider's specialty. We examined gender differences in opioid, benzodiazepine, and antibiotic prescribing for each specialty. For each specialty and drug category, we calculated the median number of claims per patient (effectively the drugs prescribed per patient), for male and female prescribers. The Mann-Whitney test was used to determine the significance of the differences between medians, statistically testing if females prescribed less than males using a Bonferroni corrected p -value threshold of .001. Instead of mean estimates, we chose to compare median prescribing because it resulted in a more robust statistic for these data (Medicare Part D is full of prescriber outliers, and the majority of them are male). To adjust for the differences in the patient populations of male and female prescribers (e.g., prescribers are more likely to treat a patient of their own gender), we applied linear models to account adjust for the differences in the patient populations, including variables for the gender balance, average risk score, and the average age of a prescriber's patients. We adjusted for the age of prescribers, creating a variable for how long the provider had been practicing, based on the year in which they

graduated from medical school. Although we performed the same analysis for all drugs, opioids, benzodiazepines, and antibiotics, due to the small number of specialties and providers that prescribe benzodiazepines, we exclude benzodiazepines when a large sample size is important (e.g., in linear modeling).

Results

Female providers accounted for 42% of the 2016 Medicare Part D prescribers, and 33% of the overall claims. Based on the analysis of provider-level prescribing patterns, we observed a consistent trend of male providers prescribing more drugs per patient than female providers, with a few exceptions by specialty.

Although we observed some variation, male providers prescribed drugs for substantially more patients across almost all of the top prescribing specialties. By provider specialty, Figure 1. shows a heatmap that visualizes the percent difference of male and female providers' median total drug cost, as well as total, opioid, and antibiotic Medicare Part D beneficiaries.

The distribution of provider prescribing by specialty and gender for different categories of drugs is shown in Figures 3, 4, 5, and 6. The box plots are sorted by the absolute difference between the median male provider and median female provider within each specialty and category. Figure 3 presents the distribution of claims per beneficiary, and we can see that in almost every specialty, the top quartile, median, and bottom quartiles are higher for male providers, demonstrating that male providers across a wide range of specialties prescribe more drugs per patient than their female counterparts, with the largest differences in Geriatric Medicine and Family Medicine. Figure 4 shows the distribution of opioid prescribing rates by specialty and gender, calculated by CMS as the percentage of all claims made by a provider that are opioid claims. Figure 4 shows that the opioid prescribing rate is higher for male providers in almost every specialty, and the differences are biggest in Anesthesiology, Dentistry, Physical Medicine and Rehabilitation and Neurosurgery. Figure 5 shows the distribution of benzodiazepine claims per beneficiary for the top benzodiazepine prescribing specialties; the biggest differences are in Psychiatry, Family Medicine, and Internal Medicine. Finally, Figure 6 shows the distribution of antibiotic claims per beneficiary for the top antibiotic prescribing specialties; the largest distributional differences are

in Family Medicine, Dentistry, and General Practice. Within Urology, female providers prescribed more antibiotics per beneficiary than male providers.

We show the median number of Medicare Part D beneficiaries for male and female providers in different specialties in Figures 7, 8, and 9. The diagonal line in each figure represents parity. Figure 7 shows the median drug beneficiaries. Across every specialty, males had more drug beneficiaries than females. Figure 8 shows the median opioid beneficiaries for every specialty. Again, in every specialty, male providers had more opioid beneficiaries than female providers. Finally, Figure 9 shows the median antibiotic beneficiaries by gender and specialty, and again, male providers had more antibiotic beneficiaries across every specialty.

After adjusting for the number of each provider's patients, the salient trend of male providers making more drug claims persisted. Based on per patient estimates, the heatmap in Figure 2. shows the percent difference of male and female providers' median total, opioid, benzodiazepine, and antibiotic Medicare Part D drug claims.

After exploring the data visually, we tested the relationships statistically using Mann-Whitney tests. As reported in our table of Mann-Whitney p values (Table 1), in 20 out of 30 top prescribing specialties, male providers made significantly more claims per beneficiary than female providers. In the 15 specialties with the most opioid claims, male providers had significantly higher opioid prescribing rates in 14 specialties (Table 2). In the 15 specialties submitting the most benzodiazepine claims, male providers made significantly more claims per beneficiary than female providers in 7 specialties (Table 3). In the 15 specialties submitting the most antibiotic claims, male providers made significantly more claims per beneficiary than female providers in 9 specialties (Table 4).

Adjusting for differences in the patient populations of male and female providers, the effect size of male gender on a provider's overall prescribing rate was significantly positive for 27 out of the top 40 prescribing specialties (Table 5), and significantly negative for 3 specialties. The effect size of male gender on a provider's opioid prescribing rate was significantly positive for 32 out of 40 specialties, and significantly

negative for 1 specialty. The effect size of male gender on a provider's antibiotic prescribing rate was significantly positive for 20 out of 40 specialties, and significantly negative for 5 specialties. Examples of very large effect sizes were opioid prescribing in anesthesiology (males made .521 more opioid claims per beneficiary), and overall prescribing in internal medicine (males made 2.268 more claims per beneficiary).

After adjusting for differences in the patient populations of male and female providers, we sought to control for other provider differences besides gender. We approximated the age of providers by calculating the number of years they have practiced medicine (calculated as 2016 minus the year in which they graduated from medical school). After filtering our data to include only providers for whom we have medical school graduation data, the number of providers in our dataset got reduced by approximately one third. The Pearson correlation of the age and gender of providers is .36 and statistically significant with a p-value of less than 2.2×10^{-16} . Table 6 shows the effect sizes of gender on prescribing per patient after adjusting for both the differences in the patient populations of male and female providers as well as for the age of providers.

As Table 6 shows, the effect size of male gender on a provider's overall prescribing rate was significantly positive for 12 out of the top 30 prescribing specialties, and significantly negative for 9 specialties; the effect size of male gender on a provider's opioid prescribing rate was significantly positive for 22 out of 30 specialties, and significantly negative for 1 specialty; and the effect size of male gender on a provider's antibiotic prescribing rate was significantly positive for 15 out of 30 specialties, and significantly negative for 8 specialties. Examples of very large effect sizes were opioid prescribing in anesthesiology (males made .274 more opioid claims per beneficiary), and overall prescribing in internal medicine (males made 1.388 more claims per beneficiary).

Discussion

Our population-based study of Medicare Part D patients found that male providers prescribed more drugs by volume and cost, as well as per patient, including more opioids, benzodiazepines, and antibiotics, than female providers. The etiology of these observed gender differences in prescribing is unknown, and is likely to be complex and multifactorial. Areas of future research could include the potential impact of patient volume, pharmaceutical payments, and/or gendered cultural differences.

Our data imply that male prescribers see more Medicare patients in a year, although we were not able to assess whether patient volume in fact reduces time per patient. Nonetheless, systemic and financial pressures to see more patients per unit time, and have ‘satisfied customers,’ may contribute to increased prescribing.⁵ Previous research has found that male physicians spend less time with their patients than female physicians⁶: shorter visits have been associated with increased prescribing.⁷ Female providers are more likely to engage in prevention-rich treatments than their male counterparts.⁸⁹¹⁰¹¹¹² Male physicians are more likely than females to receive pharmaceutical payments, which has been linked to higher prescribing of the marketed drug,¹³ and may also play a role in these data. Our data found the starkest gender differences in opioid prescribing in specialties that target pain. A study of opioid prescribing to chronic pain patients in France found no gender differences,¹⁴ suggesting the intersection between culture, opioids, and pain, may lead to gendered differences in prescribing.

Our analysis had the following key limitations. Our dataset did not necessarily reflect clinicians’ complete practice, and did not allow us to adjust for individual patient-level variables such as medical complexity. In some specialties, there was either a small sample size of female providers (urology), or a large gender imbalance (orthopedic surgery). We demonstrate significant findings, based on administrative drug claims for Medicare beneficiaries; their generalization to the population at-large is unknown.

Conclusion

Male Medicare part D providers across diverse specialties are more likely than female providers to prescribe all types of medications, including opioids, benzodiazepines, and antibiotics. This finding informs the design of prevention strategies that seek to reduce iatrogenic harms related to prescribing. Our study is the first study showing gender differences in prescribing by specialty at the population level. Future research could consider mixed methods approaches that include the analysis of more granular data sources, such as those that can be linked directly to each patient’s comprehensive care record, and qualitative studies looking at the social, economic, and cultural factors driving these observed gender differences.

Figure 1: Percent difference of male and female providers' median drug cost, and Medicare Part D beneficiaries.

Figure 2: Percent difference of male and female providers' median drug cost, and Medicare Part D beneficiaries.

Figure 3: Distribution of provider prescribing of drugs per beneficiary by specialty and gender.

From the distribution of claims per beneficiary, it is clear that in almost every specialty, the top quartile, median, and bottom quartiles are higher for male providers, demonstrating that male providers across a wide range of specialties prescribe more drugs per patient than their female counterparts, with the largest differences in Geriatric Medicine and Family Medicine.

Figure 4: Distribution of provider opioid prescribing rates by specialty and gender.

CMS calculates opioid prescribing rates as the percentage of all claims made by a provider that are opioid claims. From the distribution of opioid prescribing rates by specialty and gender, we see that the opioid prescribing rate is higher for male providers in almost every specialty, and the differences are biggest in Anesthesiology, Dentistry, Physical Medicine and Rehabilitation and Neurosurgery.

Figure 5: Distribution of provider benzodiazepine prescribing per beneficiary by specialty and gender.

The biggest differences in benzodiazepine prescribing are in Psychiatry, Family Medicine, and Internal Medicine.

Figure 6: Distribution of provider antibiotic prescribing per beneficiary by specialty and gender.

The largest distributional differences are in Family Medicine, Dentistry, and General Practice. Within Urology, female providers prescribed more antibiotics per beneficiary than male providers.

Figure 7: Provider median drug beneficiaries, by gender and specialty.

Across every specialty, males had more drug beneficiaries than females.

Figure 8: Provider median opioid beneficiaries, by gender and specialty.

In every specialty, male providers had more opioid beneficiaries than female providers.

Figure 9: Provider median antibiotic beneficiaries, by gender and specialty.

In every specialty, male providers had more antibiotic beneficiaries.

Table 1: Comparison of the median total claims per beneficiary for male and female providers by specialty.

<u>Specialty</u>	<u>Median Male</u>	<u>Median Female</u>	<u>Percent Difference</u>	<u>P value</u>	<u>Female Provider Count</u>	<u>Male Provider Count</u>
Allergy and Immunology	5.128	4.803	6.80%	2.68E-08	1,429	2,587
Anesthesiology	4.55	3.784	20.20%	0.00000197	1,437	6,061
Cardiology	7.917	7.346	7.80%	<2e-16	3,049	22,039
Dermatology	2.388	2.305	3.60%	1.89E-10	6,141	6,890
Emergency Medicine	1.5	1.469	2.10%	<2e-16	12,955	34,274
Endocrinology	8.338	7.531	10.70%	<2e-16	2,822	2,944
Family Medicine	12.434	10.122	22.80%	<2e-16	44,277	65,737
Gastroenterology	3.322	3.329	-0.20%	0.335	2,249	11,101
General Practice	11.701	10.202	14.70%	0.000418	2,878	7,293
Geriatric Medicine	16.18	13.695	18.10%	0.000000659	966	962
Hematology	6.227	5.843	6.60%	0.0411	219	460
Hematology Oncology	6.042	5.578	8.30%	<2e-16	2,723	5,601
Infectious Disease	6.034	5.83	3.50%	0.0641	2,070	3,183
Internal Medicine	7.907	6.978	13.30%	<2e-16	49,269	83,905
Nephrology	8.274	7.57	9.30%	4.42E-11	2,246	6,239
Neurology	7.229	6.807	6.20%	5.62E-11	4,189	9,468
Nurse Practitioner	3.934	3.982	-1.20%	0.984	124,571	13,243
Obstetrics and Gynecology	3.32	2.913	14.00%	<2e-16	20,018	15,680
Oncology	5.725	5.201	10.10%	8.5E-10	987	2,039
Ophthalmology	4.017	3.847	4.40%	6.86E-11	4,694	15,069
Optometry	3.204	2.777	15.40%	<2e-16	10,916	17,654
Pain Management	5.913	5.75	2.80%	0.0855	558	3,302
Pediatrics	4.462	4.545	-1.80%	0.58	5,298	6,460
Physical Medicine and Rehabilitation	4.6	4.304	6.90%	0.0115	2,733	5,669
Physician Assistant	2.139	2.482	-13.80%	1	57,697	29,036
Psychiatry	12.312	11.39	8.10%	1.17E-12	16,387	25,631
Pulmonary Disease	6.138	6.004	2.20%	0.00266	1,720	7,557
Rheumatology	7.915	7.328	8.00%	2.21E-15	1,993	2,666
Student	2.636	3	-12.10%	1	22,993	28,622
Urology	3.98	3.476	14.50%	<2e-16	958	9,752

Table 2: Comparison of the median opioid claims per beneficiary for male and female providers by specialty.

Specialty	Median Male	Median Female	Percent Difference	P value	Female Provider Count	Male Provider Count
Anesthesiology	2.391	1.683	42.10%	1.14E-10	1,129	4,996
Dentistry	0.339	0.228	48.70%	<2e-16	14,857	47,290
Emergency Medicine	0.35	0.325	7.70%	<2e-16	9,739	28,419
Family Medicine	0.507	0.387	31.00%	<2e-16	36,273	57,434
General Practice	0.411	0.279	47.30%	<2e-16	2,127	5,851
General Surgery	0.75	0.781	-4.00%	1	3,401	14,571
Hematology Oncology	0.633	0.546	15.90%	<2e-16	2,308	5,022
Internal Medicine	0.315	0.276	14.10%	<2e-16	37,007	66,062
Neurology	0.119	0.067	77.60%	<2e-16	2,806	6,950
Nurse Practitioner	0.18	0.118	52.50%	<2e-16	94,833	10,237
Orthopedic Surgery	1.004	0.935	7.40%	1.38E-12	1,119	20,685
Pain Management	3.348	2.825	18.50%	0.000287	521	3,181
Physical Medicine and Rehabilitation	1.331	0.917	45.10%	<2e-16	2,119	4,807
Physician Assistant	0.37	0.245	51.00%	<2e-16	43,196	22,936
Rheumatology	0.682	0.5	36.40%	<2e-16	1,725	2,463

Table 3: Comparison of the median benzodiazepine claims per beneficiary for male and female providers by specialty.

Specialty	Median Male	Median Female	Percent Difference	P value	Female Provider Count	Male Provider Count
Cardiology	0.098	0.095	3.20%	0.608	322	4,138
Emergency Medicine	0.103	0.12	-14.20%	0.99	437	2,332
Family Medicine	0.417	0.311	34.10%	<2e-16	22,921	39,939
General Practice	0.59	0.491	20.20%	0.00000108	1,212	3,479
Geriatric Medicine	0.373	0.274	36.10%	7.26E-09	627	678
Hematology Oncology	0.195	0.19	2.60%	0.154	1,153	2,918
Internal Medicine	0.411	0.306	34.30%	<2e-16	18,116	34,781
Neurology	0.318	0.3	6.00%	0.0283	2,308	5,962
Nurse Practitioner	0.394	0.321	22.70%	<2e-16	31,142	3,639
Pain Management	0.19	0.198	-4.00%	0.848	202	1,554
Physical Medicine and Rehabilitation	0.222	0.236	-5.90%	0.98	627	1,861
Physician Assistant	0.239	0.213	12.20%	0.00000127	9,502	4,872
Psychiatry	1.884	1.545	21.90%	<2e-16	8,663	15,148
Pulmonary Disease	0.136	0.139	-2.20%	0.655	307	2,452

Table 4: Comparison of the median antibiotic claims per beneficiary for male and female providers by specialty.

Specialty	Median Male	Median Female	Percent Difference	P value	Female Provider Count	Male Provider Count
Dentistry	1.077	1	7.70%	<2e-16	14,857	47,290
Dermatology	0.275	0.222	23.90%	<2e-16	3,984	4,171
Emergency Medicine	0.446	0.459	-2.80%	1	9,739	28,419
Family Medicine	0.434	0.35	24.00%	<2e-16	36,273	57,434
General Practice	0.528	0.47	12.30%	3.69E-12	2,127	5,851
Infectious Disease	1.869	1.816	2.90%	0.0294	1,441	2,139
Internal Medicine	0.417	0.365	14.20%	<2e-16	37,007	66,062
Nurse Practitioner	0.393	0.373	5.40%	0.0944	94,833	10,237
Oral and Maxillofacial Surgery	0.877	0.828	5.90%	0.000937	530	5,782
Orthopedic Surgery	0.218	0.209	4.30%	0.00443	1,119	20,685
Otolaryngology	0.4	0.362	10.50%	3.85E-09	946	5,827
Physician Assistant	0.416	0.399	4.30%	1.43E-09	43,196	22,936
Podiatry	0.457	0.412	10.90%	2.46E-12	2,207	8,050
Pulmonary Disease	0.425	0.42	1.20%	0.856	940	4,142
Urology	0.684	0.801	-14.60%	1	714	8,051

Table 5: Effect size of male gender on a provider's overall prescribing rate, by specialty.

Specialty	Effect Size Claims per Beneficiary	Effect Size Opioid Claims per Beneficiary	Effect Size Antibiotic Claims per Beneficiary	N (All)	N (Opioids)	N (Antibiotics)
Allergy and Immunology	0.294*** (0.100, 0.487)	0.012 (-0.012, 0.037)	0.016 (-0.009, 0.041)	3069	2419	2348
Anesthesiology	0.465* (-0.069, 0.999)	0.521*** (0.210, 0.831)	0.015 (-0.015, 0.044)	3005	2847	1447
Cardiology	1.422*** (1.266, 1.579)	0.063*** (0.050, 0.075)	0.031*** (0.021, 0.040)	23398	12571	10523
Dentistry	0.042*** (0.032, 0.053)	0.077*** (0.070, 0.084)	0.048*** (0.042, 0.053)	65681	37683	65274
Dermatology	0.322*** (0.288, 0.356)	-0.033*** (-0.041, -0.025)	-0.022*** (-0.032, -0.012)	11780	7126	10445
Emergency Medicine	0.190*** (0.119, 0.261)	0.032*** (0.023, 0.040)	-0.008*** (-0.011, -0.004)	40557	36149	39410
Endocrinology	0.836*** (0.632, 1.039)	0.034*** (0.025, 0.044)	0.033*** (0.024, 0.042)	5235	3609	2553
Family Medicine	1.826*** (1.677, 1.974)	0.221*** (0.206, 0.235)	0.127*** (0.122, 0.133)	95798	84635	88620
Gastroenterology	0.284*** (0.180, 0.389)	0.025*** (0.013, 0.037)	-0.029*** (-0.038, -0.020)	12570	6553	10636
General Practice	-0.33 (-1.000, 0.341)	0.280*** (0.203, 0.358)	0.064*** (0.044, 0.083)	7462	6080	6854
General Surgery	0.533*** (0.368, 0.698)	-0.013 (-0.035, 0.008)	-0.025** (-0.044, -0.006)	14070	13058	10427
Geriatric Medicine	5.284*** (3.853, 6.716)	0.195*** (0.122, 0.269)	0.138*** (0.095, 0.181)	1749	1630	1599
Hematology	0.538* (-0.026, 1.101)	0.228* (-0.011, 0.467)	-0.016 (-0.092, 0.061)	508	401	387
Hematology Oncology	0.328*** (0.180, 0.475)	0.108*** (0.080, 0.137)	-0.034*** (-0.047, -0.021)	7110	6689	5861
Infectious Disease	0.142 (-0.302, 0.585)	0.050** (0.010, 0.090)	0.041 (-0.023, 0.106)	3930	2541	3861
Intensivist	0.317 (-0.407, 1.041)	0.042 (-0.109, 0.192)	0.052 (-0.040, 0.144)	1070	608	821
Internal Medicine	2.268*** (2.138, 2.398)	0.183*** (0.172, 0.195)	0.074*** (0.069, 0.079)	1E+05	85622	92906
Nephrology	0.648*** (0.398, 0.897)	0.070*** (0.049, 0.092)	-0.01 (-0.025, 0.005)	7818	4915	6258
Neurology	0.471*** (0.333, 0.609)	0.224*** (0.174, 0.275)	0.005* (-0.0005, 0.010)	11391	8029	6162
Nurse Practitioner	-0.073 (-0.203, 0.057)	0.068*** (0.046, 0.091)	0.019*** (0.012, 0.026)	1E+05	80054	81249
Obstetrics and Gynecology	0.380*** (0.333, 0.427)	0.052*** (0.032, 0.072)	0.025*** (0.014, 0.036)	19314	7530	8037
Oncology	0.367*** (0.147, 0.588)	0.081*** (0.035, 0.126)	-0.016 (-0.038, 0.007)	2312	2128	1797
Ophthalmology	0.034 (-0.015, 0.084)	0.015*** (0.009, 0.020)	-0.001 (-0.008, 0.006)	17389	10382	8478
Optometry	0.299*** (0.256, 0.343)	0.001** (0.0001, 0.002)	0.012*** (0.005, 0.019)	13414	12558	5426
Orthopedic Surgery	0.266*** (0.178, 0.355)	0.169*** (0.121, 0.217)	-0.011 (-0.034, 0.011)	18636	18349	11885
Osteopathy	-2.951*** (-5.101, -0.801)	0.628*** (0.209, 1.047)	0.016 (-0.062, 0.093)	386	335	309
Otolaryngology	0.114*** (0.043, 0.186)	-0.013 (-0.031, 0.005)	0.041*** (0.026, 0.056)	8679	5801	7901
Pain Management	-0.412 (-0.912, 0.087)	0.236 (-0.054, 0.526)	0.01 (-0.009, 0.029)	3501	3449	1602
Pediatrics	-0.765 (-1.818, 0.289)	0.0004 (-0.109, 0.110)	0.031 (-0.027, 0.089)	1464	1037	1098
Pharmacology	-0.056 (-0.289, 0.178)	0.058* (-0.002, 0.118)	0.011*** (0.003, 0.020)	1620	1571	1434
Physical Medicine and Rehabilitation	0.348** (0.059, 0.638)	0.567*** (0.417, 0.717)	-0.003 (-0.024, 0.017)	6068	5611	3024
Physician Assistant	-0.071* (-0.148, 0.006)	0.141*** (0.124, 0.158)	0.019*** (0.015, 0.024)	68953	55363	55122
Podiatry	0.080*** (0.046, 0.113)	0.120*** (0.104, 0.137)	0.052*** (0.039, 0.065)	12338	8622	10887
Psychiatry	0.166 (-0.043, 0.374)	0.065*** (0.044, 0.085)	0.006*** (0.004, 0.008)	22822	15342	13272
Pulmonary Disease	0.413*** (0.177, 0.648)	0.085*** (0.051, 0.120)	-0.01 (-0.040, 0.020)	8054	4196	7387
Registered Nurse (NOS)	1.378** (0.294, 2.462)	0.169* (-0.024, 0.362)	0.071*** (0.021, 0.121)	2073	1610	1488
Rheumatology	1.105*** (0.899, 1.311)	0.372*** (0.320, 0.424)	-0.007 (-0.022, 0.008)	4321	3999	2493
Specialist (NOS)	-0.334 (-1.482, 0.814)	0.454** (0.059, 0.849)	0.067* (-0.006, 0.140)	767	562	479
Student	-0.311*** (-0.398, -0.224)	0.070*** (0.056, 0.083)	0.032*** (0.023, 0.041)	20389	12002	9608
Urology	0.653*** (0.503, 0.804)	-0.001 (-0.024, 0.023)	0.155*** (0.127, 0.184)	8843	7571	8742

Covariates included in linear model: provider gender; male ratio of providers' patients; average age of providers' beneficiaries; average risk score of providers' beneficiaries
p-values: ***: .01; **: .05; *: .1

Table 6: Effect size of male gender on a provider's overall prescribing rate (including additional covariates), by specialty.

Specialty	Effect Size Claims per Beneficiary	Effect Size Opioid Claims per Beneficiary	Effect Size Antibiotic Claims per Beneficiary	N (All)	N (Opioids)	N (Antibiotics)
Allergy and Immunology	-0.087 (-0.285, 0.110)	-0.009 (-0.031, 0.013)	-0.021 (-0.048, 0.006)	2657	2082	2070
Anesthesiology	-0.016 (-0.526, 0.494)	0.274* (-0.036, 0.583)	0.011 (-0.018, 0.041)	2569	2461	1230
Cardiology	0.809*** (0.658, 0.960)	0.039*** (0.026, 0.052)	0.011** (0.001, 0.021)	21670	11483	9710
Dermatology	0.199*** (0.168, 0.230)	-0.024*** (-0.033, -0.014)	-0.016*** (-0.027, -0.005)	10536	6287	9485
Emergency Medicine	0.147 (-0.035, 0.328)	0.022** (0.003, 0.041)	-0.012*** (-0.019, -0.005)	12671	10967	12299
Endocrinology	0.145 (-0.073, 0.364)	0.011** (0.001, 0.021)	0.009* (-0.0005, 0.019)	4731	3256	2293
Family Medicine	0.663*** (0.500, 0.827)	0.145*** (0.130, 0.160)	0.098*** (0.092, 0.104)	75742	68322	71660
Gastroenterology	-0.282*** (-0.390, -0.173)	0.007 (-0.004, 0.019)	-0.034*** (-0.043, -0.024)	11553	5976	9881
General Practice	-1.865*** (-2.719, -1.012)	0.163*** (0.070, 0.256)	0.043*** (0.016, 0.070)	4376	3804	4171
General Surgery	-0.113 (-0.282, 0.055)	-0.006 (-0.029, 0.016)	-0.087*** (-0.108, -0.067)	11999	11207	9129
Geriatric Medicine	2.887*** (1.377, 4.397)	0.100** (0.018, 0.182)	0.112*** (0.062, 0.162)	1322	1231	1204
Hematology Oncology	-0.015 (-0.169, 0.138)	0.076*** (0.047, 0.106)	-0.043*** (-0.056, -0.029)	6552	6199	5446
Infectious Disease	-0.444** (-0.888, -0.001)	0.033 (-0.007, 0.073)	0.023 (-0.045, 0.092)	3652	2345	3599
Internal Medicine	1.388*** (1.250, 1.526)	0.134*** (0.122, 0.146)	0.046*** (0.041, 0.052)	85827	71205	78225
Nephrology	-0.004 (-0.249, 0.241)	0.039*** (0.018, 0.061)	-0.020** (-0.036, -0.004)	7302	4587	5883
Neurology	-0.175** (-0.312, -0.039)	0.142*** (0.089, 0.195)	0.00001 (-0.005, 0.005)	10394	7330	5609
Nurse Practitioner	0.251*** (0.094, 0.408)	0.096*** (0.068, 0.124)	0.019*** (0.011, 0.028)	65723	50937	52979
Obstetrics and Gynecology	0.100*** (0.049, 0.151)	0.119*** (0.100, 0.137)	0.052*** (0.038, 0.065)	15540	5716	6649
Ophthalmology	-0.148*** (-0.200, -0.095)	0.020*** (0.014, 0.026)	-0.002 (-0.010, 0.005)	15581	9107	7626
Optometry	0.128*** (0.080, 0.175)	0.001* (-0.0001, 0.002)	0.015*** (0.008, 0.023)	12023	11221	4767
Orthopedic Surgery	0.053 (-0.030, 0.136)	0.093*** (0.045, 0.141)	-0.005 (-0.028, 0.018)	16805	16590	10935
Otolaryngology	0.001 (-0.057, 0.058)	0.004 (-0.010, 0.017)	0.016** (0.001, 0.032)	7684	5171	7093
Pain Management	-0.423* (-0.875, 0.029)	0.132 (-0.155, 0.418)	0.016* (-0.003, 0.035)	3103	3061	1414
Physical Medicine and Rehabilitation	0.224* (-0.040, 0.489)	0.484*** (0.329, 0.640)	0.003 (-0.015, 0.021)	5269	4900	2593
Physician Assistant	-0.323*** (-0.417, -0.229)	0.180*** (0.158, 0.201)	0.012*** (0.005, 0.018)	43111	34558	33589
Podiatry	0.040** (0.005, 0.076)	0.128*** (0.110, 0.145)	0.037*** (0.023, 0.051)	11246	7927	10049
Psychiatry	-0.661*** (-0.905, -0.416)	0.036*** (0.014, 0.059)	0.006*** (0.004, 0.008)	14725	9552	8380
Pulmonary Disease	-0.317*** (-0.554, -0.079)	0.025 (-0.007, 0.056)	-0.070*** (-0.102, -0.039)	7478	3866	6886
Rheumatology	0.327*** (0.110, 0.544)	0.235*** (0.179, 0.292)	-0.032*** (-0.049, -0.016)	3883	3615	2266
Urology	0.257*** (0.134, 0.379)	0.048*** (0.033, 0.062)	0.126*** (0.097, 0.155)	7765	6773	7710

Covariates included in linear model: years since provider graduated from medical school; male ratio of providers' patients, average age of providers' beneficiaries, average risk score of providers' beneficiaries
p-values: ***: .01; **: .05; *: .1

¹ Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration.2017.

² Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years. *JAMA Psychiatry*.2014;71(7):821–826.

³ Lembke, A., Papac, J., Humphreys, K. Our Other Prescription Drug Problem. *New England Journal of Medicine*.2018;378(8), 693-695.

⁴ Li Y., Mölter A., White A., Welfare W., Palin V., Belmonte M., Ashcroft D., Sperrin M., Staa T. P. Relationship between prescribing of antibiotics and other medicines in primary care: a cross-sectional study. *British Journal of General Practice*.2019; 69 (678): e42-e51.

⁵ Lembke, A. Why Doctors Prescribe Opioids to Known Opioid Abusers. *New England Journal of Medicine*.2012;367(17), 1580-1581.

⁶ Roter DL, Hall JA, Aoki Y. Physician Gender Effects in Medical Communication: A Meta-analytic Review. *JAMA*. 2002;288(6):756–764.

⁷ Dugdale DC, Epstein R, Pantilat SZ. Time and the patient-physician relationship. *J Gen Intern Med*. 1999;14(Suppl 1):S34–S40.

⁸ Frank, E. Prevention advice rates of women and men physicians. *Archives of Family Medicine*. 1996;5(4), 215–219.

⁹ Franks, P., & Bertakis, K. D. Physician Gender, Patient Gender, and Primary Care. *Journal of Women's Health*.2003;12(1), 73–80.

¹⁰ Lurie, N., Slater, J., McGovern, P., Ekstrum, J., Quam, L., Margolis, K. Preventive Care for Women -- Does the Sex of the Physician Matter? *New England Journal of Medicine*.1993; 329(7), 478–482.

¹¹ Dahrouge, S., Seale, E., Hogg, W., Russell, G., Younger, J., Muggah, E., Mercer, J. A Comprehensive Assessment of Family Physician Gender and Quality of Care. *Medical Car*. 2016;54(3), 277–286.

¹² Hohmann, A. Gender Bias in Psychotropic Drug Prescribing in Primary Care. *Medical Care*. 1989;27(5), 478-490.

¹³ Larkin I, Ang D, Steinhart J, et al. Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing. *JAMA*. 2017;317(17):1785–1795.

¹⁴ Lazkani, A., Delespierre, T., Benattar-Zibi, L., Bertin, P., Corruble, E., Derumeaux, G., Becquemont, L. Do Male and Female General Practitioners Differently Prescribe Chronic Pain Drugs to Older Patients? *Pain Medicine*. 2015;16(4), 696–705.